Live event on safety on compounded GLP-1s
GLP-1 drugs are rapidly transforming the treatment of obesity, diabetes and a growing range of chronic conditions, offering new promise for improved health outcomes. However, the unprecedented growth of compounded drugs are raising questions about regulation enforcement, safety and oversight, and the potential impact of newer distribution models.
Join Axios Live in Washington, D.C., for an event examining the evolving GLP-1 landscape. We’ll talk about the promise of these therapies, the risks and regulatory challenges surrounding non-FDA approved compounded versions, and what the next phase could mean for patients, providers, policymakers and industry.
Axios congressional reporter Stef Kight and health tech deals reporter Brock Turner will host one-on-one conversations with:
- The Honorable Nikki Budzinski, Representative, Illinois's 13th Congressioonal District, Member, House Agriculture and Veterans' Affairs Committees
- Scott Kahan, M.D., M.P.H., F.T.O.S., Director, National Center for Weight and Wellness
- Shabbir Imber Safdar, CFE, Executive Director, Partnership for Safe Medicines
- View From the Top segment moderated by Eugene Scott
- The Honorable Rudy Yakym, Representative, Indiana's 2nd Congressional District, Member, House Ways and Means Committee
7:30am | Doors open
8:00am | Mainstage conversations
9:00am | Event concludes